Bassler Bonnie L has engaged in a clear pattern of net selling across two companies—Regeneron Pharmaceuticals (REGN) and Royalty Pharma (RPRX)—with $5.8 million in total sales outweighing $2.5 million in purchases over 30 transactions. The bulk of the activity centers on Regeneron, where six recent sales since January 2024, including a $1.2 million disposition on January 7, 2026, and a $570,000 sale on November 20, 2025, demonstrate a consistent reduction in holdings. Smaller, periodic acquisitions of RPRX shares—such as a $37,471 purchase on March 31, 2026—appear routine, likely tied to equity awards given their consistent quarterly timing and modest size. The only other activity involves derivative transactions in Cidara Therapeutics (CDTX), though these were either valueless or minimal, such as a $3,322.50 disposition. The data reveals a sustained divestment trend in Regeneron, contrasting with the steady but minor accumulation of RPRX shares, suggesting a strategic reallocation or liquidity focus rather than broad portfolio growth.
AI-assisted summary